Stockscreener 앱 받기
34.82
2.56%
0.87
시간 외 거래:
34.82
전일 마감가:
$33.95
열려 있는:
$33.96
하루 거래량:
3.10M
Relative Volume:
2.68
시가총액:
$3.75B
수익:
-
순이익/손실:
$-176.01M
주가수익비율:
-20.96
EPS:
-1.661
순현금흐름:
$-148.97M
1주 성능:
+5.77%
1개월 성능:
+5.23%
6개월 성능:
+56.07%
1년 성능:
+140.30%
1일 변동 폭
$33.72
$35.48
1주일 범위
$30.84
$36.90
52주 변동 폭
$12.15
$40.77
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
34.82 | 3.79B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 개시 | Goldman | Neutral |
| 2025-07-30 | 개시 | Raymond James | Strong Buy |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-04-30 | 개시 | Guggenheim | Buy |
| 2025-04-02 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-22 | 개시 | Stifel | Hold |
| 2024-11-22 | 개시 | Evercore ISI | Outperform |
| 2024-03-07 | 개시 | Piper Sandler | Overweight |
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
모두보기
엣지와이즈 주식(EWTX)의 최신 뉴스
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PR Newswire
(EWTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Number of shareholders of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView
Edgewise Therapeutics, Inc. 2026 Annual Meeting Results and SEC Filing Details - Minichart
Edgewise Therapeutics Shareholders Back Board and Governance - TipRanks
Edgewise Therapeutics (EWTX) shareholders approve directors, KPMG and executive pay - Stock Titan
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement - Seeking Alpha
Paradigm Biocapital Advisors LP's Edgewise Therapeutics Inc(EWTX) Holding History - GuruFocus
Liquidity Mapping Around (EWTX) Price Events - Stock Traders Daily
Edgewise Therapeutics Reports Inducement Grants As Permitted By Nasdaq Listing Rules - TradingView
Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - 富途牛牛
Guggenheim Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX) - The Globe and Mail
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal - Medical Dialogues
New Edgewise hires get 74,000 stock options as hiring inducement - Stock Titan
Edgewise sells sevasemten for up to $2.65 billion - The Pharma Letter
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal - The Globe and Mail
Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move - Yahoo Finance
EWTX Maintained by HC Wainwright & Co. -- Price Target Raised to $45 - GuruFocus
EWTX Maintained by Wedbush -- Price Target Raised to $52.00 - GuruFocus
RBC Capital lowers Edgewise Therapeutics stock price target on deal By Investing.com - Investing.com Australia
RBC Capital lowers Edgewise Therapeutics stock price target on deal - Investing.com
RBC Lowers Price Target on Edgewise Therapeutics to $48 From $50, Keeps Outperform, Speculative Risk - marketscreener.com
Wedbush raises Edgewise Therapeutics stock price target on Servier deal - Investing.com UK
Wedbush raises Edgewise Therapeutics stock price target on Servier deal By Investing.com - Investing.com India
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn - Yahoo Finance
Edgewise Therapeutics, IBM, Rubrik - TradingView
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics - MedCity News
Edgewise Therapeutics (EWTX) Surges 17.5% on Market Activity - GuruFocus
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang - Investor's Business Daily
Servier to Acquire Edgewise Therapeutics (EWTX) for $2.65 Billio - GuruFocus
Raymond James raises Edgewise Therapeutics price target on Servier deal By Investing.com - Investing.com Canada
Edgewise Therapeutics stock hits all-time high of 40.6 USD By Investing.com - Investing.com South Africa
Servier Pharmaceuticals LLC and LES LABORATOIRES SERVIER, SAS entered into an Asset Purchase Agreement to acquire Sevasemten and Muscular Dystrophy Business of Edgewise Therapeutics, Inc. for $2.7 billion.. - marketscreener.com
Edgewise sells muscular dystrophy assets to Servier for $2.65B - BioWorld News
Servier buys into muscular dystrophy with potentially $2.7B deal - BioPharma Dive
Edgewise Therapeutics Shares Surge 15% to $39.40 on Promising Muscle Disease Treatment Data - International Business Times Australia
Why is Edgewise Therapeutics stock surging today? By Investing.com - Investing.com Canada
EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business - Yahoo Finance
Servier Agrees to Acquire Muscular Dystrophy Business of Edgewise Therapeutics - Contract Pharma
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn - European Biotechnology Magazine
Edgewise Therapeutics Sells Sevasemten, Refocuses on Cardiology - TipRanks
Edgewise Therapeutics stock hits all-time high of 40.6 USD - Investing.com
Edgewise Therapeutics Sells Sevasemten for Up to $2.65 Billion, Refocuses on Cardiovascular Pipeline - Minichart
Servier projette d'acquérir l'activité dystrophie musculaire d'Edgewise Therapeutics - PR Newswire
Edgewise sells muscular dystrophy unit to Servier for $2.65B By Investing.com - Investing.com Australia
Servier to acquire Edgewise muscular dystrophy unit for $2.65b By Investing.com - Investing.com South Africa
France: Servier acquires muscular dystrophy business of Edgewise Therapeutics for up to US$2.65bn - Investors in Healthcare
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business - The Manila Times
Edgewise sells muscular dystrophy unit to Servier for $2.65B - Investing.com
Edgewise Therapeutics (EWTX) to sell sevasemten business to Servier for up to $2.65B - Stock Titan
Edgewise's Muscular Dystrophy Business to be Acquired by Servier for Up to $2.65 Billion - marketscreener.com
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엣지와이즈 주식 (EWTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Donovan Joanne M. | CMO |
May 05 '26 |
Option Exercise |
7.08 |
50,000 |
354,000 |
54,367 |
| Donovan Joanne M. | CMO |
May 05 '26 |
Sale |
38.57 |
50,000 |
1,928,400 |
4,367 |
| Donovan Joanne M. | CMO |
May 04 '26 |
Sale |
31.29 |
5,230 |
163,663 |
4,367 |
| Donovan Joanne M. | CMO |
Apr 01 '26 |
Option Exercise |
7.08 |
28,662 |
202,927 |
38,259 |
| Donovan Joanne M. | CMO |
Apr 01 '26 |
Sale |
32.31 |
28,662 |
926,095 |
9,597 |
| Donovan Joanne M. | CMO |
Mar 31 '26 |
Option Exercise |
7.08 |
21,338 |
151,073 |
30,935 |
| Donovan Joanne M. | CMO |
Mar 31 '26 |
Sale |
32.12 |
21,338 |
685,308 |
9,597 |
| Donovan Joanne M. | CMO |
Mar 27 '26 |
Sale |
30.98 |
16,358 |
506,735 |
9,597 |
2.60%
0.94%
자본화:
|
볼륨(24시간):